MedTrace Logo

Improving Sexual Function After Myocardial Infarction

NCT05312320 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2022-11-16

No results posted yet for this study

Summary

The study is completely digital. Men and women who recently had an MI will be invited through a written brochure that will be present in all Norwegian departments of cardiology. Post-MI patients can check the investigators web site (www.sefh.no) to determine whether they are eligible for the study. After consent and answering the baseline questionnaire, each participant will be randomized to either the intervention or control group.

Control group: Standard surveillance after MI (no specific focus on sexual activity and functioning) Intervention group: Online sexual counselling including a short information film.

In order to assess the generalizability of the results, we will compare the age, sex and MI treatment of the respondents with data on Norwegian MI-patients in general.

Conditions

Interventions

OTHER

Information film

* Sexual activity after MI does not increase risk of recurrence or death * Sexual activity is associated with improved outcome after MI * Resuming sexual activity as normal is recommended and completely safe

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Sorlandet Hospital HF

    lead OTHER_GOV

Principal Investigators

  • Frode Gallefoss · Sorlandets hospital HF

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2023-11-30
Completion
2024-11-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312320 on ClinicalTrials.gov